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SUMMARY Recent studies have shown a correlation between an 
increased number of mast cells in patients with atopic dermatitis (AD) 
resulting in raised plasma levels of nerve growth factor (NGF), pointing 
to a possible key role of their interaction in the pathogenesis of AD. It 
is well known that mast cells synthesize, store and release NGF. Mast 
cells and NGF both appear to be involved in tissue inflammation and 
neuroimmune interactions, with NGF acting as a general “alert” molecule 
capable of recruiting and priming both local tissue and systemic defense 
processes following stressful events. Also, NGF has been demonstrated 
to increase mast cell histamine content and intracellular tryptase activity 
in a dose- and time-dependent fashion. Endogenous aliamides are 
capable of down-regulating mastocyte reactivity by their action through 
the vanilloid (VR1) receptors, and keratinocytes, and through the CB1 
and CB2 cannabinoid receptors linked to G-protein, also expressed by 
sensitive nerve endings, macrophages, and epithelial cells. Therefore, 
aliamide action should be regarded as a multifaceted mechanism 
interfering with the inflammatory process occurring in AD further beyond 
the known and controversial anti-histamine pharmacologic effect. In 
this regard, the reduction of mast cell degranulation by adelmidrol, as 
demonstrated by in vitro and in vivo investigations in animals, would 
interfere with the release of other inflammatory mediators, including 
NGF. Based on these considerations, a pilot study aimed to assess 
the efficacy and safety of twice daily application of a topical emulsion 
containing adelmidrol 2%, a novel aliamide, in a series of 20 patients (11 
male and 9 female, mean age 8 (range 3-16) years) affected by mild AD 
was performed. Complete resolution with no side effects was observed 
in 16 (80%) patients after 4 weeks of treatment, with no relapses at 
8-week follow up. Six patches in six subjects with multiple lesions that 
had not been treated and served as controls showed no improvement. 
Controlled clinical studies in larger series are warranted to confirm the 
efficacy of aliamide in the management of AD.
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INTRODUCTION 
 Atopic dermatitis (AD) is a chronic inflamma-
tory skin disorder associated with cutaneous hy-
perreactivity to environmental triggers. Its cause 
is believed to be multifactorial. The clinical AD 
phenotype is the result of the interaction between 
susceptibility genes, environmental influences, a 
defective skin barrier function, and an altered im-
mune response (1). Mast cells also play a patho-
genetic role in AD. They are abundantly localized 
in the dermis close to the epidermis and blood 
vessels, where they play a pivotal role in hyper-
sensitivity responses by releasing histamine and 
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other mediators causing pruritus. Moreover, they 
may stimulate neoangiogenesis, and contribute 
to maintaining chronic inflammation by enhancing 
transportation through the new vessels of comple-
ment components and antibodies, together with 
inflammatory cells (2).
 AD in pediatric patients is particularly problem-
atic, as children are more susceptible to entering 
the itch-scratch cycle, where constant scratching 
of the skin exacerbates the condition. Addressing 
the itch is of primary concern to patients and their 
caregivers, who are often distressed by the child’s 
symptoms. Therapy of mild AD is based on the 
use of topical corticosteroids, non-steroidal anti-
inflammatory agents, topical immunomodulators, 
and the regular daily use of emollients. Topical 
corticosteroids are associated with side effects, 
and patients and physicians would prefer to avoid 
their extended usage if possible. A non-steroidal 
method of managing patients with AD would there-
fore be welcome. This is particularly true in chil-
dren, who are more susceptible to potential sys-
temic adverse effects of topical corticosteroids. 
 In the past few years, a novel mechanism of 
local modulation of mast cell function by spe-
cific endocannabinoids belonging to the class of 
aliamides, known as “autacoid local inflammation 
antagonism” (ALIA), has been elucidated (3).
 Based on these considerations, a pilot study 
aimed to assess the efficacy and safety of a topi-
cal emulsion containing adelmidrol 2% (Table 1), a 
novel aliamide, in the treatment of mild AD in pedi-
atric subjects, was performed at our Department.
PATIENTS AND METHODS
 Twenty patients (11 male and nine female), 
mean age 8 (range 3-16) years, affected by mild 
AD were enrolled. Inclusion criteria were: male or 
female children and adolescents aged between 
2 and 16 years, diagnosed with mild AD at study 
entry according to Hanifin and Rajka criteria (4) 
and based on the Investigator Global Assess-
ment (IGA) score (5). Exclusion criteria were: 
moderate to severe AD, presence of severe ex-
coriation, coexistence of skin disorders other than 
AD, including active bacterial, fungal or viral skin 
infections, use of other topical or systemic treat-
ments for AD in the 4 weeks prior to baseline. Fol-
lowing informed consent signed by both parents, 
participants were instructed to apply the study drug 
twice daily for 4 weeks. Six areas in six subjects 
with multiple lesions were not treated and served 
as controls. Efficacy was assessed by objectively 
recording the degree of erythema and infiltration 
according to the IGA score and the patient assess-
ment of pruritus relief at subsequent visits.
RESULTS
 Improvement of erythema and pruritus was evi-
dent in 12 (60%) patients soon after 10-15 days of 
treatment. Clinical resolution was observed in 16 
(80%) patients after 4 weeks of treatment (Figs. 
1 and 2), with no relapses at a 4-week follow up. 
Untreated lesions showed no improvement. No 
treatment-related side effects were observed in 
any subject during the study.
DISCUSSION AND CONCLUSION
 The role of histamine release in the pathogene-
sis of pruritus in AD and evidence for the beneficial 
use of antihistamines is still a matter of specula-
tion (6). Recent studies have shown a correlation 
between an increased number of mast cells in pa-
tients with AD resulting in raised plasma levels of 






Figure 1. Nummular lesion on the left cheek of a 
6-year-old child before (a) and after (b) treatment 
with topical adelmidrol 2% cream for 4 weeks.
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nerve growth factor (NGF), pointing to a possible 
key role of their interaction in the pathogenesis of 
AD (7-9). It is well known that mast cells synthe-
size, store and release NGF (10). Mast cells and 
NGF both appear to be involved in tissue inflam-
mation and neuroimmune interactions, with NGF 
acting as a general “alert” molecule capable of re-
cruiting and priming both local tissue and systemic 
defense processes following stressful events (11). 
Also, NGF has been demonstrated to increase 
mast cell histamine content and intracellular trypt-
ase activity in a dose- and time-dependent fash-
ion, leading to mast cell hyperactivity, enhanced 
degranulation, and boost in the release of proin-
flammatory mediators causing erythema, edema 
and pruritus.
 Aliamides are a new class of pharmacologi-
cal agents that possess a peculiar mechanism 
of action that does not simply rely on histamine 
antagonism. Endogenous aliamides are capable 
of down-regulating mastocyte reactivity by their 
action through the vanilloid (VR1) receptors, non-
selective cationic canals also expressed by type 
C nerve endings, and keratinocytes, and through 
the CB1 and CB2 cannabinoid receptors linked to 
G-protein (12), also expressed by sensitive nerve 
endings, macrophages, and epithelial cells (13).
Therefore, aliamide action should be regarded 
as a multifaceted mechanism interfering with the 
inflammatory process occurring in AD further be-
yond the known and controversial anti-histamine 
pharmacological effect. In this regard, the reduc-
tion of mast cell degranulation by adelmidrol, as 
demonstrated by in vitro (3) and in vivo investiga-
tions in animals (3), would interfere with the re-
lease of other inflammatory mediators, including 
NGF. This would explain the mechanism of action 
of adelmidrol cream in our series of patients af-
fected by mild AD.
 The positive clinical response, with complete 
clearing of treated lesions in 80% of patients, sug-
gests that this new topical agent may represent a 
promising tool for the management of this disorder 
(14). Controlled clinical studies in larger series are 
warranted to confirm the efficacy of aliamides in 
the management of AD.
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